Drowning in the magic well: Shaman pharmaceuticals and the elusive value of traditional knowledge

Journal of Environment and Development

Volumn 11, Issue 1, 2002, Pages 79-102

  Clapp, Roger Alex ^a   Crook, Carolyn ^b  

^a SIMON FRASER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; INDIGENOUS POPULATION; PHARMACEUTICAL INDUSTRY; RISK FACTOR; TRADITIONAL KNOWLEDGE;

EID: 0036195530     PISSN: 10704965     EISSN: None     Source Type: Journal    
DOI: 10.1177/107049650201100104     Document Type: Article

References (91)

1. When pharma merges, R and D is the dowry
2. The role of plant screening and plant supply in biodiversity conservation, drug development, and health care
3. Natural product drug discovery and development: New perspectives on international collaboration
4. Ethnopharmacological studies and biological conservation in Belize
5. Anthropological issues in medical ethnobotany
6. Synergistic use of combinatorial and natural product chemistry
7. Synthetic combinatorial libraries: A new tool for antimicrobial agent discovery
8. From Shaman pharmaceuticals to Shaman botanicals
9. The pharmaceutical industry
10. Rain forest entrepreneurs: Cashing in on conservation
11. Shaman Pharmaceuticals' approach to drug development
12. The ethnobotanical approach to drug discovery: Strengths and limitations
13. Policies for international collaboration and compensation in drug discovery and development at the United States National Cancer Institute, the NCI Letter of Collection
14. Natural products in drug discovery and development
15. Is market-oriented forest conservation a contradiction in terms?
16. Development of pharmaceutical companies based on plant products: Suggested approaches
17. Drug discovery: A historical perspective
18. Ethnopharmacology and its role in Third World countries
19. Screening plants for new medicines
20. Ethnopharmacology and drug development
21. Potential consequence of plant extinction in the United States on the current and future availability of prescription drugs
22. Biodiversity prospecting: Potentialities for developing countries
23. Mechanism-based target identification and drug discovery in cancer research
24. The value of biodiversity: Markets, society, and ecosystems
25. Recent developments in drug discovery technologies
26. The origins of prescription drugs
27. Western medicine men return to the field
28. Pharmaceutical discovery, ethnobotany, tropical forests, and reciprocity: Integrating indigenous knowledge, conservation, and sustainable development
29. Establishing reciprocity: Biodiversity, conservation, and new models for cooperation between forest-dwelling peoples and the pharmaceutical industry
30. Conservation and tropical medicinal plant research
31. Biological diversity, indigenous knowledge, drug discovery, and intellectual property rights
32. From shaman to human clinical trials: The role of industry in ethnobotany, conservation, and community reciprocity
33. A central natural product pool - New approach in drug discovery strategies
34. Prostratin: Activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART
35. Natural products and the pharmaceutical industry
36. Ethnopharmacology and the search for new therapeutics
37. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
38. Cryptolepis sanguinolenta: An ethnobotanical approach to drug discovery and the isolation of a potentially useful new antihyperglycemic agent
39. Update: Shaman pharmaceuticals
40. The value of undiscovered pharmaceuticals in tropical forests
41. Returning benefits from ethnobotanical drug discovery to native communities
42. Biopharmaceutics and pharmacokinetics in drug research
43. The economic value of plant-based pharmaceuticals
44. The evolving status of herbals and phytomedicines in the United States
45. Valuing the biodiversity of medicinal plants
46. Valuing research leads: Bioprospecting and the conservation of genetic resources
47. Translating genetic resource rights into sustainable development: Gene cooperatives, the biotrade, and lessons from the Philippines
48. A new lease on life
49. The value of sangre de drago
50. Reporting biological assay results on tropical medicinal plants to host country collaborators
51. Equitable sharing of biodiversity benefits: Agreements on genetic resources
52. Target-oriented and diversity-oriented organic synthesis in drug discovery
53. Property rights, externalities, and biodiversity
54. Shaman positioned to provide natural medicine alternatives
55. Valuing biodiversity for use in pharmaceutical research
56. Ethnobotany in the search for vasoactive herbal medicines
57. Drug firms enter industry
58. Creating biodiversity: Bioprospecting for the next blockbuster drug
59. Automation strategies in drug discovery
60. Are prescription drug prices high?
61. It's a jungle out there